Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

2 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

SFXN2 adjusts cell proliferation in multiple myeloma

ABSTRACT: SFXN2 adjusts cell proliferation in multiple myeloma

ORGANISM(S): Homo Sapiens

SUBMITTER: Ye Yang

PROVIDER: PXD027607 | iProX | Wed Jul 28 00:00:00 BST 2021

REPOSITORIES: iProX

ACCESS DATA

Json Xml

Publications

Elevated SFXN2 limits mitochondrial autophagy and increases iron-mediated energy production to promote multiple myeloma cell proliferation.

Chen Ying Y Qian Jinjun J Ding Pinggang P Wang Wang W Li Xinying X Tang Xiaozhu X Tang Chao C Yang Ye Y Gu Chunyan C

Cell death & disease 20220926 9

Human sideroflexin 2 (SFXN2) belongs to the SFXN protein family, which is a mitochondrial outer membrane protein involved in mitochondrial iron metabolism. Mitochondria are indispensable for cellular energy production and iron metabolism. However, it remains elusive how SFXN2 modulates mitochondrial homeostasis and cellular iron metabolism in multiple myeloma (MM). In this study, we first found that SFXN2 was significantly elevated and correlated to poor outcomes in MM patients from clinical dat ...[more]

PMID: 36163342

Similar Datasets

Multiple myeloma

Project description:Multiple myeloma

| PRJNA515992 | ENA

Normal plasma cells,Low proliferation multiple myeloma and High proliferation multiple myeloma cells

Project description:CD138 sorted bone marrow plasma cell were obtained from a normal patient, a multiple myelow with slow proliferation and a multiple myelow with rapid proliferation.

2015-06-20 | ST000221 | MetabolomicsWorkbench

DOT1L inhibition blocks multiple myeloma cell proliferation through suppressing IRF4-MYC signaling

Project description:DOT1L inhibition blocks multiple myeloma cell proliferation through suppressing IRF4-MYC signaling

| PRJNA428234 | ENA

Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

Project description:This clinical trial studies peripheral blood hemapoietic stem cell mobilization with the combination of bortezomib and G-CSF (filgrastim) in multiple myeloma and non-Hodgkin lymphoma patients.

| 2158857 | ecrin-mdr-crc

miRNA profiling of multiple myeloma, MGUS, multiple myeloma cell lines and normal plasma cells

Project description:miRNA profiling in multiple myeloma - microRNAs represent a class of noncoding regulators of gene expression implicated in several biological and pathophysiological processes, including cancer. We investigate here their role in multiple myeloma using miChip-arrays interrogating 559 miRNAs in 92 purified myeloma-, MGUS-, normal plasma cell- and myeloma cell line samples. Impact on gene expression is assessed by Affymetrix U133 2.0 DNA-microarrays in 741 samples including two cohorts of 332 and 345 myeloma patients; chromosomal aberrations are assessed by iFISH, survival for 247 and 345 patients undergoing up-front high-dose therapy and autologous stem cell transplantation. Compared to normal plasma cells, 67/559 (12%) miRNAs are differentially expressed with fold changes of 4.6 to -3.1 in myeloma-, 20 (3.6%) in MGUS-samples, and three (0.5%) between MGUS- and myeloma-samples. Expression of miRNAs is associated with biological and pathophysiological parameters, i.e. proliferation, chromosomal aberrations, e.g. t(4;14), tumor mass, and gene expression-based high-risk scores. This holds true for target-gene signatures of regulated mRNAs. miRNA-expression confers prognostic significance for event-free (72/559) and overall survival (69/559), as do respective target-gene signatures. In conclusion, the miRNome of myeloma confers a pattern of small changes of individual miRNAs compared to normal plasma cells impacting on gene expression, biological functions, and survival.

2014-01-09 | E-MTAB-1363 | biostudies-arrayexpress

Multiple Myeloma cells

Project description:Multiple Myeloma cells

| PRJNA800411 | ENA

Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in Multiple Myeloma

Project description:Che-1/AATF-induced transcriptionally active chromatin promotes cell proliferation in Multiple Myeloma

| PRJNA627186 | ENA

CD229 promotes multiple myeloma cell proliferation by regulating RAS/ERK pathway

Project description:Flag antibody was used for immunoprecipitation, and cd229-OE partial binding protein was searched by protein spectrum in CD229-OE multiple myeloma cell line, and its interaction was analyzed.

2022-03-09 | PXD032177 | iProX

Serum protein N-glycosylation changes in multiple myeloma

Project description:<h4><strong>BACKGROUND:</strong> Multiple myeloma is characterized by clonal proliferation of malignant plasma cells in the bone marrow that produce monoclonal immunoglobulins. N-glycosylation changes of these monoclonal immunoglobulins have been reported in multiple myeloma, but previous studies only detected limited serum N-glycan features.</h4><h4><strong>METHODS:</strong> Here, a more detailed study of the human serum N-glycome of 91 multiple myeloma patients and 51 controls was performed. We additionally analyzed sequential samples from patients (n = 7) which were obtained at different time points during disease development as well as 16 paired blood serum and bone marrow plasma samples. N-glycans were enzymatically released and measured by mass spectrometry after linkage specific derivatization of sialic acids.</h4><h4><strong>RESULTS:</strong> A decrease in both α2,3- and α2,6-sialylation, galactosylation and an increase in fucosylation within complex-type N-glycans were found in multiple myeloma patients compared to controls, as well as a decrease in difucosylation of diantennary glycans. The observed glycosylation changes were present in all ISS stages, including the 'low-risk' ISS I. In individual patients, difucosylation of diantennary glycans decreased with development of the disease. Protein N-glycosylation features from blood and bone marrow showed strong correlation. Moreover, associations of monoclonal immunoglobulin (M-protein) and albumin levels with glycan traits were discovered in multiple myeloma patients.</h4><h4><strong>CONCLUSIONS & GENERAL SIGNIFICANCE: </strong>In conclusion, serum protein N-glycosylation analysis could successfully distinguish multiple myeloma from healthy controls. Further studies are needed to assess the potential roles of glycan trait changes and the associations of glycans with clinical parameters in multiple myeloma early detection and prognosis.</h4>

2022-04-27 | MTBLS676 | MetaboLights

Study on the effect and mechanism of GART in regulating the proliferation of multiple myeloma

Project description:Study on the effect and mechanism of GART in regulating the proliferation of multiple myeloma

2023-09-26 | PXD045718 | iProX